Pulmonary arterial hypertension (PAH) is a progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH is a very rare condition that occurs when pulmonary arteries become narrow in diameter or get blocked. This report on the global pulmonary arterial hypertension (PAH) market offers an insightful and in-depth assessment of the current and future market potential of PAH drugs. The research study has been divided into eight chapters namely, preface, executive summary, global PAH market overview, global PAH market revenue by drug class, PAH market pipeline analysis, global PAH market revenue by geography, recommendations, and company profiles.

This 73 page report gives readers a comprehensive overview of the Pulmonary Arterial Hypertension (PAH) Market. Browse through 14 data tables and 22 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html

According to the market report, the global PAH market has been evaluated on the basis of drug classes and regional distribution. Prostacyclin, prostacyclin analogs, PDE-5 inhibitors, ERAs, and sGC stimulators are the key drugs available in the global market to treat PAH. ERAs led the global market in 2013, accounting for a market share of 55.8% in terms of revenue.

Analysts, however, have predicted that the market for prostacyclin and prostacyclin analogs will surpass the ERAs market by the end of the forecast period. The launch of the recently approved Orenitram is likely to propel this market segment during the forecast period. The approval for Uptravi, which is slated in Q1 of 2016, is also anticipated to add to the market segment’s growth prospects, notes the research study.North America, Europe, Asia Pacific, and the Rest of the World are the key regional markets for pulmonary arterial hypertension across the world. Among these, the PAH market in North America led the global market with a share of 44.6% in 2013 and was closely followed by the Europe PAH market.

Over the forecast period, both these regional markets are expected to exhibit remarkable growth, owing to the availability of newly-approved PAH drugs as well as products waiting to gain approval in these markets.The Asia Pacific market for PAH is also projected to show significant development in the next few years. India, China, Japan, New Zealand, and Australia are likely to present opportunity-rich markets for enterprises operating in the global PAH market. On the other hand, the Rest in the World PAH market is facing severe challenges, owing to the low awareness level pertaining to the detection and treatment of pulmonary arterial hypertension, states the market study.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Pulmonary Arterial Hypertension (PAH) Market by 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5627

The major players operating in the global market for pulmonary arterial hypertension are Actelion Pharmaceuticals Ltd., Gilead Sciences Inc., Bayer HealthCare, GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, and United Therapeutics Corp., states the research report.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/